Combining Lunesta and Ativan: Safety and Recommendations
Lunesta (eszopiclone) and Ativan (lorazepam) should not be routinely combined due to additive CNS depression, increased sedation, and heightened risk of complex sleep behaviors, though pharmacokinetic studies show no drug-drug interaction on elimination. 1
FDA Warning on Concurrent Use
The FDA label for Lunesta explicitly states that it "may produce additive CNS-depressant effects when coadministered with other psychotropic medications" and specifically warns that "dose adjustment may be necessary when LUNESTA is administered with other CNS-depressant agents, because of the potentially additive effects." 1 The label further emphasizes that alcohol and other CNS depressants increase the risk of complex behaviors like sleep-driving when used with eszopiclone at any dose. 1
Pharmacokinetic Evidence
No elimination interference: When eszopiclone (the S-enantiomer of zopiclone) and lorazepam were coadministered, they decreased each other's Cmax by only 22% without altering elimination pharmacokinetics. 1
Short-duration interaction: A study of zopiclone (racemic mixture containing eszopiclone) with lorazepam found that while psychomotor impairment increased acutely after concurrent administration, the effect was short-lived due to rapid elimination of zopiclone, with only slight impairment persisting 6-8 hours post-dose. 2
Clinical Risk Profile
Pharmacodynamic concerns outweigh the lack of pharmacokinetic interaction:
Enhanced sedation and psychomotor impairment occur when these agents are combined, particularly in the first 1-6 hours after administration. 2
Complex sleep behaviors (sleep-driving, sleep-eating, amnesia) are more likely when eszopiclone is combined with other CNS depressants, even at therapeutic doses. 1
Respiratory depression risk, though not quantified in available studies, is a theoretical concern with dual GABA-ergic agents, particularly in vulnerable populations. 1
When Combination Might Be Considered
If clinical circumstances require both medications:
Separate timing: Administer lorazepam for daytime anxiety management and reserve eszopiclone strictly for bedtime use, ensuring several hours of separation. 1
Reduce eszopiclone dose: Start at 1 mg (rather than the standard 2 mg) when any CNS depressant is co-prescribed. 1
Monitor closely: Watch for excessive daytime sedation, falls (especially in elderly), memory impairment, and any complex sleep behaviors. 1
Avoid in elderly: Patients ≥65 years already require lower eszopiclone doses (1-2 mg maximum) due to 41% increased drug exposure and prolonged elimination; adding lorazepam substantially increases fall and confusion risk. 1
Preferred Alternatives
Rather than combining these agents, consider:
Cognitive behavioral therapy for insomnia (CBT-I) as first-line treatment, reserving pharmacotherapy for adjunctive use. 3
Monotherapy optimization: Maximize the efficacy of one agent before adding another—eszopiclone 2-3 mg is effective for both sleep onset and maintenance. 3, 4
Non-benzodiazepine anxiolytic: If daytime anxiety requires treatment alongside insomnia, consider SSRIs or buspirone rather than lorazepam to avoid compounding sedation. 1
Common Pitfalls to Avoid
Do not assume "no pharmacokinetic interaction" means "safe to combine"—the pharmacodynamic interaction (additive CNS depression) is the primary concern. 1
Do not take eszopiclone after a high-fat meal when combined with lorazepam, as delayed absorption may lead to overlapping peak effects the next morning. 1
Do not continue combination therapy long-term—both agents carry dependence risk, and concurrent use may accelerate tolerance development. 1